Summarized by Masters of Longevity from Longevity Technology.
Analysis of venture capital shifting toward later, larger, de‑risked investments in biotech, concentrating funding into fewer, well‑capitalized longevity companies.
Key Takeaways
- Investment into longevity rose from $4.7 billion in 2024 to $18.4 billion in 2025 with $12.1 billion committed in 2026.
- About 44% of 2025 disclosed funding went into larger rounds for a smaller cohort of companies.
- Cellular reprogramming drew outsized capital, including NewLimit raising $610 million and Retro Biosciences raising about $1 billion.
